Modality
ERT
MOA
CD47i
Target
WEE1
Pathway
Lipid Met
Cervical CaNSCLC
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
Oct 2019
Phase 1Current
NCT04934968
1,068 pts·Cervical Ca
2019-10→TBD·Completed
1,068 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Q4
P1/2
Complet…
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04934968 | Phase 1/2 | Cervical Ca | Completed | 1068 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| BGN-3859 | BeiGene | Approved | PSMA |